Introduction: Hypoglycemia is the most common adverse effect of diabetes therapy,
INTRODUCTION
Diabetes is characterized by elevated blood glucose levels (hyperglycemia) and is associated with considerable morbidity and mortality [1, 2] . Good glycemic control with intensive treatment prevents or delays microvascular complications, and reduces cardiovascular and all-cause mortality [3, 4] .
Therefore, a key clinical goal in the treatment and management of diabetes is to achieve good glycemic control with minimal hypoglycemia or other adverse effects of treatment. The recommended general glycemic target is a glycated hemoglobin (HbA 1c ) level \7% [5] [6] [7] . The most common and highly feared adverse effect of diabetes therapy, particularly insulin, is hypoglycemia, which occurs when the plasma glucose level becomes too low [8] .
Hypoglycemia can occur suddenly and with varying severity. Severe events are categorized as those requiring the assistance of another person, whereas non-severe events do not require assistance [9] [10] [11] . Hypoglycemia has been shown to negatively impact on quality of life and productivity in the workplace [10, 12, 13] . Fear of hypoglycemia can have a behavioral impact on diabetes management and metabolic control. To avoid hypoglycemia, patients may reduce or omit an insulin dose, which may result in sub-optimal glucose control and increase the risk of long-term complications [14, 15] .
Hypoglycemia is not only associated with considerable cost to the individual in terms of wellbeing, it also represents a substantial cost burden to healthcare systems and society [16] . The total costs to the National Health Service, of managing non-severe and severe hypoglycemia in insulin-treated adults in the UK (population 64.1 million), were recently estimated at £172.1 million and £295.9 million per annum, respectively [17] .
It can be difficult to accurately determine the frequency of hypoglycemic events due to differences in methods of data collection and the lack of a consistent clinical definition of hypoglycemia. Non-severe hypoglycemia is particularly underestimated as patients infrequently report these events to their physicians [18] . Randomized controlled trials (RCTs) remain the most reliable source of clinical evidence and are the gold standard for demonstrating clinical efficacy. However, the stringent constraints of a clinical trial setting, and the selection of patients enrolled, may limit the generalizability of RCTs to routine clinical practice. Other sources of evidence, such as real-world data (RWD), can be used to fill this gap and complement the available RCT evidence [19] . The use of RWD from sources such as databases, patient medical chart reviews and registries, and prospective and retrospective studies is increasingly being recognized as a valuable additional source of information to inform decision making and improve patient access to new drugs [19, 20] . While there is no standardized definition of RWD, they are generally defined as data that are not collected in conventional RCTs [21] . RWD can provide the evidence for a treatment outside the tight constraints of a clinical trial setting, for example for patients excluded from trials, and patients whose treatment is determined by clinical practice rather than trial protocol. RWD can both complement and build on the evidence base established by RCTs and can be of particular benefit in the study of large, heterogeneous patient populations with complex, chronic diseases such as diabetes [22] .
The aim of the current study was to compare the frequency of hypoglycemic events reported in real-world settings with those reported in clinical trials. A structured literature review was conducted to identify hypoglycemic event rates in patients with T1DM and T2DM using insulin in real-world settings and RCTs. This study was intended only as an observational analysis.
METHODS
A search was conducted in PubMed to identify published literature that reported hypoglycemic event rates in patients with T1DM and T2DM treated with insulin. The search was conducted on 9 December 2014 and was restricted to Due to the nature of data collection in RWD studies, there was no restriction placed on duration. Studies of interest were restricted to those with total study populations C400 patients; this was to ensure a large enough patient population for a reasonable estimation of severe hypoglycemia rates, without too great a restriction on the number of studies included in the final dataset [25] . Only studies that defined the diabetes population (i.e. T1DM or T2DM) and the insulin regimen (basal insulin only, basal-bolus, or premix) were included. Eligibility criteria for the studies of interest are shown in Table 1 . The original eligibility criteria for RWD studies specified any study reporting RWD, with the exception of case studies.
However, a decision was made to exclude all database studies upon assessment of full text.
This was because the majority of RWD database studies are based on insurance claim databases, where patients only tend to make a claim for incidences of severe and emergency-related hypoglycemic events, and thus, they do not provide an accurate representation of overall hypoglycemia in the real-world setting.
HbA 1c target and mean end-of-trial HbA 1c level were recorded, if reported, due to the relationship between HbA 1c levels and hypoglycemia risk.
Hypoglycemia Definition
For the purposes of this study, we considered three categories of hypoglycemia-severe, 
RESULTS
The original literature search identified 2171 potentially relevant studies. After removal of duplicates, 1974 citations were screened on the basis of title and abstract and any studies not meeting the inclusion criteria were excluded (n = 1750). A total of 224 full-text publications were assessed for eligibility whereupon a further 194 studies were excluded. Reasons for exclusion included: population B400; RCT study duration \26 weeks; and hypoglycemia event rates not reported. The final included (Fig. 1 ).
The majority of RCTs identified in the literature search had a treat-to-target design whereby insulin doses are force-titrated to achieve a pre-specified glycemic target [26] . In general, HbA 1c targets were consistent across RCTs with targets of B6.5% or 7.0% (Supplementary Tables I-IV) .
Results are presented by diabetes population (T1DM, T2DM on basal-oral therapy, T2DM on basal-bolus therapy, and T2DM on premix insulin), as rates of hypoglycemia vary according to diabetes type/duration and Fig. 1 Flow diagram of the literature search. Hypo hypoglycemia, NR not reported, RCT randomized controlled trial, RWD real-world data. Other reasons included type of diabetes not specified, insulin regimen not specified, study data reported elsewhere as part of a main study insulin regimen. Studies will be represented more than once if they report on more than one diabetes population.
T1DM
Six studies (RWD, n = 2; RCT, n = 4) reported hypoglycemia event rates in people with T1DM
[27-32]. For all reported categories of hypoglycemia (severe, non-severe, and nocturnal), rates were consistently higher in the RWD studies than the RCTs ( RCT randomized controlled trial, RWD real-world data, T1DM type 1 diabetes mellitus, T2DM type 2 diabetes mellitus [56] . Similarly, older ([75 years) people may have a tendency toward hypoglycemia due to malnutrition and comorbidities [57] . In addition, patients enrolled in RCTs are usually subjected to more intensive monitoring and support than patients in routine clinical practice.
There are well documented limitations of RWD, such as the potential for bias with non-randomized data and inconsistent data collection. However, guidelines have been developed to provide more uniformity for such studies [58] The rates of all categories of hypoglycemia in patients with T2DM were lower than those observed in patients with T1DM, as would be expected. In patients with T2DM receiving a basal-oral therapy regimen, there was overlap in reported hypoglycemia rates between RCTs and RWD studies; however, the highest rates of hypoglycemia, for all categories, were observed in a real-world setting. The RWD study with the lowest reported hypoglycemia rates recorded hypoglycemic events as adverse drug reactions only, rather than a pre-defined outcome [33] .
The RWD study [32] that reported higher rates was a retrospective study specifically designed to investigate the frequency of non-severe and severe hypoglycemia in patients with diabetes in seven European countries [32] . As this study was designed to record hypoglycemic events, it is more likely to be an accurate reflection of the frequency of hypoglycemia in patients with diabetes.
In T2DM patients receiving a basal-bolus insulin regimen, the highest rates of severe and non-severe hypoglycemia were observed in RWD studies, whereas the highest rate of nocturnal hypoglycemia was observed in an RCT. Although again, there was a large degree of overlap in reported rates between the RWD studies and the RCTs. Only one of the five RCTs in this group reported the rate of severe hypoglycemia, the remainder simply reported number of patients who experienced a severe event; this is likely due to the low number of severe events in these studies. The higher rate of nocturnal hypoglycemia in the RCTs was driven by one study, an insulin intensification study [48] . [60] . Unless a study has been designed to record all categories of hypoglycemic events, it is likely that hypoglycemia event rates will be under-reported. A final consideration is that studies utilizing self-reporting of hypoglycemic events may be subject to recall bias.
When assessing full-text citations for potential inclusion in the current study, it was observed that the majority of studies that did report hypoglycemia incidence only reported the proportion of patients experiencing the event rather than actual event rates. Studies that report only the percentages of patients experiencing a hypoglycemic event cannot be used to estimate the true incidence of hypoglycemia as they do not provide any hypoglycemia compared with patients with \5 years duration of T1DM [8] . The study also reported that longer duration of insulin treatment ([5 years) was associated with increased rates of mild hypoglycemia in T2DM
patients compared with those with shorter duration of insulin treatment [8] .
It should also be noted that study design and how the data were collected could influence the results. For example, a retrospective analysis is likely to underestimate the true incidence of hypoglycemic events, compared with a prospective study. Similarly, there might be differences in results depending on whether the data were derived from patient diaries, or whether they were based on the results of continuous glucose monitoring. 
CONCLUSION
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